The plasma concentration of fleroxacin (FLRX) was significantly lower (P<0.05) than the control at 0.5 and 1 hour but was significantly (P<0.05) higher at 4, 8, 12 and 24 hurs after the simultaneous oral administration of FLRX with sodium valproate (VPA). The pharmacokinetic parameters, the volume of distribution (Vd) and the area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) were 1.2-and 2.3-times higher, while the elimination half-life (T1/2) and time to maximum plasma concentration (Tmax), were delayed by 2.9-and 2.6-times after the simultaneous administration with VPA and all changes were significant (P<0.05). In addition, the absorption rate constant (Ka) and clearanse (CL) were, in contrast, 0.5 and 0.5 times lower than the control, and the difference was also significant (P<0.05). The unbound flaction (%) of FLRX in the plasma increased 54 to 80% at 2 minutes and to 76% at 15 minutes after the intravenous administration of VPA. On the other hand, the total levels of FLRX decreased by 31.9 and 27.7% at 2 and 15 minutes after the intravenous administration of VPA, respectively.
The plasma concentration of fleroxacin (FLRX) was significantly lower (P<0.05) than the control at 0.5 and 1 hour but was significantly (P<0.05) higher at 4, 8, 12 and 24 hurs after the simultaneous oral administration of FLRX with sodium valproate (VPA). The pharmacokinetic parameters, the volume of distribution (Vd) and the area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) were 1.2-and 2.3-times higher, while the elimination half-life (T1/2) and time to maximum plasma concentration (Tmax), were delayed by 2.9-and 2.6-times after the simultaneous administration with VPA and all changes were significant (P<0.05). In addition, the absorption rate constant (Ka) and clearanse (CL) were, in contrast, 0.5 and 0.5 times lower than the control, and the difference was also significant (P<0.05). The unbound flaction (%) of FLRX in the plasma increased 54 to 80% at 2 minutes and to 76% at 15 minutes after the intravenous administration of VPA. On the other hand, the total levels of FLRX decreased by 31.9 and 27.7% at 2 and 15 minutes after the intravenous administration of VPA, respectively. Blood samples were collected at 0, 2, 15 and 30 minutes after injection of VPA.
Determination of total and free plasma Fleroxacin concentration described under materials and methods.
